Adventures in CAR-T Racing: Crashes and Curves Edition – Motley Fool
Motley Fool |
Adventures in CAR–T Racing: Crashes and Curves Edition
Motley Fool Just eight days after Juno Therapeutics announced its setback, bluebird bio shared some positive data for bb2121, a CAR-T therapy that reengineers T–cells to target B-cell maturation antigen (BCMA) in multiple myeloma patients. Neither Juno nor Kite … |
